News
A Big Test Is Looming for Pfizer, Moderna, and Novavax
Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong. But these companies are all preparing for what's
Better Buy: Medtronic vs. Intuitive Surgical
The stock market appears to be gradually recovering from the disaster that was 2022. So far this year, the S&P 500 has gained 16%. While the stock market goes through ups and downs, investing in
Is Regeneron's Stock in Trouble After This FDA Rejection?
Regeneron Pharmaceuticals' (NASDAQ: REGN) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for
Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation Dexcom
3 Spectacular Dividend Stocks to Buy in July
A new month is here. And with it comes a new opportunity to invest in spectacular dividend stocks.
Three Motley Fool contributors think they know some great candidates to buy in July. Here's why
Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys
Drug companies Merck (NYSE: MRK) and AbbVie (NYSE: ABBV) have been two of the best pharmaceutical investments, easily delivering better total returns than the S&P 500 average over the past three
3 Magnificent Dividend Stocks to Buy Hand Over Fist in July
Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.
However
Vertex Pharmaceuticals Stock: Bear vs. Bull
Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults
1 Green Flag and 1 Red Flag for Pfizer
Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron
Pfizer Just Canned One of Its Ozempic Killers. What's Next?
On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any
Why Shares of Alvotech Are Jumping Friday
Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
Things have not quite gone as hoped lately for shares of Sarepta Therapeutics (NASDAQ: SRPT). Recently, the biotech received approval from the Food and Drug Administration (FDA) for its cutting-edge
Why Shares of Opko Health Jumped on Thursday
Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric
What Will Amgen Buy Next?
Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of
5 High-Yielding Dividend Stocks That Are Bargain Buys
If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking. The tech sector has been attracting more attention of late due to the hype around artificial
Better Artificial Intelligence Stock: Medtronic or Arista Networks?
Artificial intelligence (AI) is an umbrella term for the use of computer vision, machine learning, and natural language processing to empower machines to do things that usually require human
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.
Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks
Whether you're saving for retirement, want to set aside money for travel, or just want to give yourself a raise, dividend stocks can help give you some extra income to accomplish those goals. Plus
Better Artificial Intelligence Stock: GSK or Eli Lilly?
Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of
Why Shares of Orchestra BioMed Holdings Jumped Wednesday
Shares of Orchestra BioMed Holdings (NASDAQ: OBIO) were up more than 16% as of 1:30 p.m. on Wednesday, as investors piled in on what looked like a bargain after the healthcare stock hit a low the
What Will AbbVie Buy Next?
AbbVie (NYSE: ABBV) is facing a tough year ahead. The company's blockbuster drug Humira, which treats various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, will
Why Shares of Structure Therapeutics Rose Monday
Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The
Why Amgen Stock Slumped on Monday
Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a
Why Pfizer Stock Is Tanking Today
Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning.
The big dip came